No Data
No Data
New Additions to Roth MKM's ADR Portfolio for September
H.C. Wainwright Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Verona Pharma Price Target Maintained With a $36.00/Share by HC Wainwright & Co.
Verona Pharma's Growth Prospects Bolstered by Clinical Advancements and Regulatory Milestones
Verona Pharma Analyst Ratings
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
loading...
loading...